Deciphering Resistance Mechanisms and Novel Strategies to Overcome Drug Resistance in Ovarian Cancer: a Comprehensive Review

Overview

Journal Oncol Res

Specialty Oncology

Date 2024 Apr 30

PMID 38686048

Authors

Effat Alemzadeh

Leila Allahqoli

Afrooz Mazidimoradi

Esmat Alemzadeh

Fahimeh Ghasemi

Hamid Salehiniya

Ibrahim Alkatout

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is among the most lethal gynecological cancers, primarily due to the lack of specific symptoms leading to an advanced-stage diagnosis and resistance to chemotherapy. Drug resistance (DR) poses the most significant challenge in treating patients with existing drugs. The Food and Drug Administration (FDA) has recently approved three new therapeutic drugs, including two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and niraparib) and one vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) for maintenance therapy. However, resistance to these new drugs has emerged. Therefore, understanding the mechanisms of DR and exploring new approaches to overcome them is crucial for effective management. In this review, we summarize the major molecular mechanisms of DR and discuss novel strategies to combat DR.

Citing Articles

Therapeutic potential of chalcone-1,2,3-triazole hybrids as anti-tumour agents: a systematic review and SAR studies.

Priya S, Islam M, Kasana S, Kurmi B, Gupta G, Patel P Future Med Chem. 2025; 17(4):449-465.

PMID: 39886772 PMC: 11834451. DOI: 10.1080/17568919.2025.2458450.

Modulation of FOXP3 Gene Expression in OVCAR3 Cells Following Rosmarinic Acid and Doxorubicin Exposure.

Toprak V, Ozdemir I, Ozturk S, Yanar O, Kizildemir Y, Tuncer M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770446 PMC: 11676701. DOI: 10.3390/ph17121606.

Cellular and molecular aspects of drug resistance in cancers.

Shaik R, Malik M, Basavaraju S, Qurban J, Al-Subhi F, Badampudi S Daru. 2024; 33(1):4.

PMID: 39652186 PMC: 11628481. DOI: 10.1007/s40199-024-00545-8.

Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma.

Rahman M, Ali M Cancers (Basel). 2024; 16(17).

PMID: 39272834 PMC: 11394361. DOI: 10.3390/cancers16172975.

References

Zamwar U, Anjankar A . Aetiology, Epidemiology, Histopathology, Classification, Detailed Evaluation, and Treatment of Ovarian Cancer. Cureus. 2022; 14(10):e30561. PMC: 9676071. DOI: 10.7759/cureus.30561. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Zeller C, Dai W, Steele N, Siddiq A, Walley A, Wilhelm-Benartzi C . Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-76. DOI: 10.1038/onc.2011.611. View

Vassal G, Geoerger B, Morland B . Is the European pediatric medicine regulation working for children and adolescents with cancer?. Clin Cancer Res. 2013; 19(6):1315-25. DOI: 10.1158/1078-0432.CCR-12-2551. View

Chan S, Wong V, Qin S, Chan H . Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2015; 34(1):83-90. DOI: 10.1200/JCO.2015.61.5724. View

Hata A, Engelman J, Faber A . The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015; 5(5):475-87. PMC: 4727530. DOI: 10.1158/2159-8290.CD-15-0011. View

Delou J, Souza A, Souza L, Borges H . Highlights in Resistance Mechanism Pathways for Combination Therapy. Cells. 2019; 8(9). PMC: 6770082. DOI: 10.3390/cells8091013. View

Kapse-Mistry S, Govender T, Srivastava R, Yergeri M . Nanodrug delivery in reversing multidrug resistance in cancer cells. Front Pharmacol. 2014; 5:159. PMC: 4090910. DOI: 10.3389/fphar.2014.00159. View

Green A, Rose P . Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 2007; 1(3):229-39. PMC: 2426807. View

10.

Safaei R, Holzer A, Katano K, Samimi G, Howell S . The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem. 2004; 98(10):1607-13. DOI: 10.1016/j.jinorgbio.2004.05.006. View

11.

Caffrey P, Frenkel G . Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol. 2000; 46(1):74-8. DOI: 10.1007/s002800000127. View

12.

Feng S, Li J, Luo Y, Yin T, Cai H, Wang Y . pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS One. 2014; 9(6):e100732. PMC: 4071001. DOI: 10.1371/journal.pone.0100732. View

13.

Liu Y, Li Z, Wang J, Li X, Huang Q, Huang Y . Effects of hepatitis C virus infection on the safety of chemotherapy for breast cancer patients. Breast Cancer Res Treat. 2017; 164(2):379-383. DOI: 10.1007/s10549-017-4259-8. View

14.

Abdullah L, Chow E . Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013; 2(1):3. PMC: 3565873. DOI: 10.1186/2001-1326-2-3. View

15.

Ciccolini J, Mercier C, Dahan L, Andre N . Integrating pharmacogenetics into gemcitabine dosing--time for a change?. Nat Rev Clin Oncol. 2011; 8(7):439-44. DOI: 10.1038/nrclinonc.2011.1. View

16.

Berek J, Renz M, Kehoe S, Kumar L, Friedlander M . Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:61-85. PMC: 9298325. DOI: 10.1002/ijgo.13878. View

17.

Erber R, Eichelsbacher U, Powajbo V, Korn T, Djonov V, Lin J . EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 2006; 25(3):628-41. PMC: 1383533. DOI: 10.1038/sj.emboj.7600949. View

18.

Horwitz S . Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994; 5 Suppl 6:S3-6. View

19.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

20.

Vaidyanathan A, Sawers L, Gannon A, Chakravarty P, Scott A, Bray S . ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer. 2016; 115(4):431-41. PMC: 4985349. DOI: 10.1038/bjc.2016.203. View